Employees: 246
Size Arvinas (ARVN) is a United States Health Care company (Biotechnology) with a market value of $443M, the 2761st largest of 3,085 United States companies the cockpit tracks. Shares closed at $6.76 on 18 Nov 2026.
Performance Over six months the shares fell 25.7%, against -9.3% for the median peer and -2.2% for the United States market (cap-weighted) — 5th lowest of 19 in its peer set.
Growth Revenue fell 11.8% over the last twelve months (peer median +4.8%); the operating margin is -10.1% (peer median -4.5%).
Backlog Backlog (remaining performance obligations) was $190M at 31 Mar 2026, down 27% on a year earlier — 2.1 years of trailing revenue. Backlog detail →
Short interest Short interest is 8.8% of the free float (30 Oct 2026).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $275M | $263M | $263M | $78.5M | $131M |
| Revenue growth | — | 0% | +236% | -40% | — |
| Gross profit | $262M | $257M | $257M | $71.8M | $123M |
| EBITDA | -$23.2M | -$110M | -$200M | -$395M | -$255M |
| Net income | -$9.50M | -$80.8M | -$199M | -$367M | -$282M |
| Free cash flow | -$160M | -$276M | -$261M | -$351M | -$280M |
| Capital expenditure | $1.50M | $1.90M | $1.80M | $2.90M | $6.80M |
| Total debt | $7.60M | $9.10M | $9.90M | $3.40M | $5.50M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ARVN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.7% | -11.6% | 11th highest of 21 |
| 6-month return | -25.7% | -9.3% | 5th lowest of 19 |
| Distance from 52-week high | -53.4% | -38.9% | 6th lowest of 21 |
| Revenue growth (TTM) | -11.8% | +4.8% | 4th lowest of 16 |
| Operating margin | -10.1% | -4.5% | 8th lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Arvinas ARVN | United States | $443M | -26% | -12% | -10% | n/a | n/a | n/a |
| EirGenix 6589.TW | Taiwan | $444M | +15% | +58% | -51% | 9.9× | n/a | n/a |
| IRulya Therapeutics IRLA | United States | $440M | +88% | n/a | n/a | n/a | n/a | n/a |
| Berry Genomics 000710.SZ | China | $439M | -17% | -2% | -24% | 3.3× | n/a | n/a |
| Qingdao Vland Biotech 603739.SS | China | $437M | -24% | +5% | 7% | 2.2× | 7.7% | +7.3% |
| Scinopharm Taiwan 1789.TW | Taiwan | $435M | -2% | -5% | -4% | 4.0× | 2.1% | +0.5% |
| Qurient 115180.KS | South Korea | $452M | -56% | -14% | -512% | 84.4× | n/a | n/a |
| Komipharm International 041960.KS | South Korea | $454M | -2% | -6% | -1% | 11.8× | n/a | n/a |
| Shattuck Labs STTK | United States | $455M | -28% | -100% | n/a | n/a | n/a | n/a |
| Prothena PRTA | United States | $429M | -11% | +347% | -73% | 3.1× | n/a | n/a |
| Qyuns Therapeutics 2509.HK | Hong Kong | $428M | -11% | +230% | 56% | 2.6× | -19.5% | n/a |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $427M | +11% | +13% | 47% | 12.3× | 5.3% | +70.5% |
| HanchorBio 7827.TW | Taiwan | $462M | n/a | n/a | -4,673% | 509.6× | n/a | n/a |
| Medigen Vaccine Biologics 6547.TWO | Taiwan | $424M | -8% | +44% | -5% | 14.6× | n/a | n/a |
| DiaMedica Therapeutics DMAC | United States | $463M | +50% | n/a | n/a | n/a | n/a | n/a |
| Shanghai ZJ Bio-Tech 688317.SS | China | $422M | -22% | -10% | -72% | 2.9× | 4.0% | -62.3% |
| Kamada KMDA | United States | $465M | +3% | +5% | 15% | 2.0× | 5.0% | +6.5% |
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $470M | n/a | n/a | n/a | n/a | n/a | n/a |
| Rznomics 476830.KS | South Korea | $418M | -76% | -65% | -1,112% | 215.1× | n/a | n/a |
| Candel Therapeutics CADL | United States | $417M | -31% | n/a | n/a | n/a | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $471M | +37% | +71% | 5% | 6.4× | 58.8% | +204.7% |
Arvinas reported $190M of remaining performance obligations at 31 Mar 2026, down 27% from a year earlier and down 8% from the previous quarter. That is 2.1 years of trailing revenue already under contract. Book-to-bill last quarter: 0.00.